Future research endeavors could benefit from addressing these limitations and incorporating complementary approaches to enhance the depth and reliability of our understanding regarding the potential risks associated with SGLT2 inhibitor use in individuals with diabetes. This evidence concerns the gene SLC5A2 and diabetes mellitus.